138 related articles for article (PubMed ID: 38054837)
1. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
Jen WY; Sasaki K; Rausch CR; DiNardo CD; Kadia TM; Yilmaz M; Borthakur G; Alvarado Y; McCue D; McCue D; Kantarjian HM; Ravandi F
Leuk Lymphoma; 2024 Mar; 65(3):378-382. PubMed ID: 38054837
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of arsenic trioxide dosing in obese patients with acute promyelocytic leukemia.
Barsoum B; Henneman A; Ahmad S; Ghiuzeli C
Leuk Lymphoma; 2021 Mar; 62(3):703-708. PubMed ID: 33107373
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide dose capping to decrease toxicity in the treatment of acute promyelocytic leukemia.
Zacholski K; Hambley B; Hickey E; Kashanian S; Li A; Baer MR; Duong VH; Newman MJ; DeZern A; Gojo I; Smith BD; Levis MJ; Varadhan R; Gehrie E; Emadi A; Ghiaur G
J Oncol Pharm Pract; 2022 Sep; 28(6):1340-1349. PubMed ID: 34134554
[TBL] [Abstract][Full Text] [Related]
4. Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia.
Freyer CW; Peterson CE; Man Y; Przespolewski A; Baron J; Luger SM
Leuk Lymphoma; 2021 Mar; 62(3):696-702. PubMed ID: 33106056
[TBL] [Abstract][Full Text] [Related]
5. Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment.
Zhang Z; Zhang S; Zhang F; Zhang Q; Wei H; Xiu R; Zhao Y; Sui M
Biol Trace Elem Res; 2024 Jan; 202(1):122-132. PubMed ID: 37097388
[TBL] [Abstract][Full Text] [Related]
6. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
7. Sulfhydryl compound levels are associated with ATO-induced side effects in acute promyelocytic leukemia patients.
Sui M; Wei H; Shen X; Gao K; Zhang Z; Zhang Q
Hematology; 2023 Dec; 28(1):2231738. PubMed ID: 37417768
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
9. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with ATRA and oral-ATO from 1991 to 2021.
Gill H; Raghupathy R; Lee CYY; Yung Y; Chu HT; Ni MY; Xiao X; Flores FP; Yim R; Lee P; Chin L; Li VWK; Au L; Au WY; Ma ESK; Mohan D; Kumana CR; Kwong YL
BMC Cancer; 2023 Feb; 23(1):141. PubMed ID: 36765318
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.
Hu J; Liu YF; Wu CF; Xu F; Shen ZX; Zhu YM; Li JM; Tang W; Zhao WL; Wu W; Sun HP; Chen QS; Chen B; Zhou GB; Zelent A; Waxman S; Wang ZY; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3342-7. PubMed ID: 19225113
[TBL] [Abstract][Full Text] [Related]
11. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.
Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L
Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide and all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia in all risk groups: study protocol for a randomized controlled trial.
Zhang X; Zhang H; Chen L; Wang M; Xi J; Liu X; Xie M; Li D; Gulati ES; Gong S; Wang H
Trials; 2018 Sep; 19(1):476. PubMed ID: 30185214
[TBL] [Abstract][Full Text] [Related]
13. Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: a variant form of the differentiation syndrome?
Vassilakopoulos TP; Asimakopoulos JV; Plata E; Kelepesis G; Petevi K; Koutsi C; Papageorgiou L; Tsaftaridis P; Angelopoulou MK; Konstantopoulos K; Meletis J
Leuk Lymphoma; 2017 Jul; 58(7):1743-1746. PubMed ID: 27919176
[No Abstract] [Full Text] [Related]
14. Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report.
He H; An R; Hou J; Fu W
Front Med; 2017 Jun; 11(2):284-286. PubMed ID: 28425042
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial myopathy caused by arsenic trioxide therapy.
Echaniz-Laguna A; Benoilid A; Vinzio S; Fornecker LM; Lannes B; Goullé JP; Broly F; Mousson de Camaret B
Blood; 2012 May; 119(18):4272-4. PubMed ID: 22427206
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
17. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC
Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855
[TBL] [Abstract][Full Text] [Related]
19. Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Coombs CC; Tavakkoli M; Tallman MS
Blood Cancer J; 2015 Apr; 5(4):e304. PubMed ID: 25885425
[TBL] [Abstract][Full Text] [Related]
20. Acute renal failure, gastrointestinal bleeding, and cardiac arrhythmia after administration of arsenic trioxide for acute promyelocytic leukemia.
Cashin R; Burry L; Peckham K; Reynolds S; Seki JT
Am J Health Syst Pharm; 2008 May; 65(10):941-6. PubMed ID: 18463343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
